We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-11.18%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.48B
AUM Growth
-$398M
Cap. Flow
+$373M
Cap. Flow %
6.82%
Top 10 Hldgs %
68.73%
Holding
45
New
4
Increased
20
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$185M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$178M
3
ARGX icon
argenx
ARGX
+$84.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$39.5M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$34.3M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$272M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$115M
3
UTHR icon
United Therapeutics
UTHR
+$953K
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$844K
5
NUVL
Nuvalent
NUVL
+$773K

Sector Composition

Rank Sector Weight
1 Healthcare 94.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$684M 12.48%
6,500,000
-2,795,000
-30% -$272M
UTHR icon
2
United Therapeutics
UTHR
$25.9B
$544M 9.92%
3,030,000
-5,000
-0.2% -$953K
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$480M 8.77%
9,450,000
+894,445
+10% +$39.5M
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$438M 7.99%
5,325,000
+250,000
+5% +$25.6M
ARGX icon
5
argenx
ARGX
$54.9B
$396M 7.22%
1,255,000
+290,000
+30% +$84.3M
XBI icon
6
State Street SPDR S&P Biotech ETF
XBI
$9.97B
$274M 5%
3,050,000
+2,000,000
+190% +$185M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.6B
$258M 4.71%
2,200,000
+200,000
+10% +$23.2M
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.64B
$245M 4.47%
3,135,000
+10,000
+0.3% +$766K
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.9B
$234M 4.27%
3,035,000
+235,000
+8% +$19.7M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$38.1B
$212M 3.88%
1,300,000
+225,000
+21% +$34.3M
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$194M 3.54%
20,500,000
+2,000,000
+11% +$18.8M
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
$189M 3.46%
+1,315,000
New +$178M
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.15B
$152M 2.78%
4,985,000
– –
IOVA icon
14
Iovance Biotherapeutics
IOVA
$2.03B
$152M 2.77%
9,125,000
+450,000
+5% +$6.96M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.4B
$140M 2.55%
1,425,000
– –
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$122M 2.23%
7,250,000
– –
KURA icon
17
Kura Oncology
KURA
$785M
$77.2M 1.41%
4,800,000
+800,000
+20% +$11.6M
KRYS icon
18
Krystal Biotech
KRYS
$10.6B
$66.9M 1.22%
1,005,000
+530,000
+112% +$33.1M
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.45B
$55.1M 1.01%
2,275,000
+75,000
+3% +$1.81M
GLUE icon
20
Monte Rosa Therapeutics
GLUE
$1.82B
$46.4M 0.85%
3,311,434
– –
PMVP icon
21
PMV Pharmaceuticals
PMVP
$57.6M
$45.8M 0.84%
2,200,000
+735,000
+50% +$13M
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.68B
$38.6M 0.7%
2,220,500
+45,500
+2% +$766K
DSGN icon
23
Design Therapeutics
DSGN
$741M
$35.9M 0.66%
2,222,222
+586,122
+36% +$8.98M
KYMR icon
24
Kymera Therapeutics
KYMR
$8.6B
$34.6M 0.63%
816,500
+266,500
+48% +$11.3M
MNKD icon
25
MannKind Corp
MNKD
$1.2B
$32.4M 0.59%
8,800,000
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Avoro Capital Advisors held 45 positions worth $5.48B, down 6.8% from $5.88B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors deployed $373M of net new capital in Q1 2022, opening 4 new positions and adding to 20 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,315,000 shares worth $189M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $272M trimmed.

  • Avoro Capital Advisors's largest Q1 2022 buy was Seagen Inc. Common Stock: 1,315,000 shares worth $189M.
  • Avoro Capital Advisors added most to State Street SPDR S&P Biotech ETF in Q1 2022, an estimated $185M increase.
  • Avoro Capital Advisors's biggest Q1 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $272M.
  • Avoro Capital Advisors fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $115M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.48B portfolio in Q1 2022.
  • Avoro Capital Advisors opened 4 new positions and closed 2 in Q1 2022.
  • Avoro Capital Advisors's portfolio value fell 6.8% quarter-over-quarter to $5.48B.

Based on Avoro Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.